Drew Ranieri
Stock Analyst at Morgan Stanley
(1.35)
# 1,513
Out of 4,641 analysts
160
Total ratings
39.08%
Success rate
-16.23%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $12.98 | +46.38% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $19.19 | +40.70% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $5.31 | +50.66% | 12 | Jul 15, 2024 | |
| GMED Globus Medical | Maintains: Equal-Weight | $67 → $71 | $73.33 | -3.18% | 10 | Jul 15, 2024 | |
| SYK Stryker | Maintains: Equal-Weight | $345 → $350 | $366.02 | -4.38% | 8 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $18.10 | +21.55% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $6.00 | +33.33% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $5.38 | +197.40% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $0.56 | +874.83% | 10 | Dec 4, 2023 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $3 → $3.5 | $3.10 | +12.90% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $18.66 | +103.64% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $74.47 | +28.91% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $22.50 | +15.56% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $239.71 | +23.07% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $236.71 | +18.29% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $12.97 | -61.45% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $36.59 | +91.31% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $517.50 | -42.03% | 6 | Apr 25, 2022 |
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $12.98
Upside: +46.38%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $19.19
Upside: +40.70%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $5.31
Upside: +50.66%
Globus Medical
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $67 → $71
Current: $73.33
Upside: -3.18%
Stryker
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $345 → $350
Current: $366.02
Upside: -4.38%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $18.10
Upside: +21.55%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $6.00
Upside: +33.33%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $5.38
Upside: +197.40%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $0.56
Upside: +874.83%
Organogenesis Holdings
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $3 → $3.5
Current: $3.10
Upside: +12.90%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $18.66
Upside: +103.64%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $74.47
Upside: +28.91%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $22.50
Upside: +15.56%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $239.71
Upside: +23.07%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $236.71
Upside: +18.29%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $12.97
Upside: -61.45%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $36.59
Upside: +91.31%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $517.50
Upside: -42.03%